Novavax reported $-345829000 in Operating Profit for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Adamas Pharmaceuticals ADMS:US -9155000 370K
Adma Biologics ADMA:US $ -15.58M 0.42M
Agenus AGEN:US $ -66.4M 25.02M
AstraZeneca AZN:LN 1.13B 768M
Astrazeneca AZN:US 1.13B 768M
Biocryst Pharmaceuticals BCRX:US $ -29.58M 21.8M
Dynavax Technologies DVAX:US $ 3.94M 24.59M
Genocea Biosciences GNCA:US $ -14.55M 2.12M
Geron GERN:US $ -28.89M 0.44M
GlaxoSmithKline GSK:LN 1.68B 18M
Kindred Biosciences KIN:US -8544000 622K
Mannkind MNKD:US $ -32.4M 26.21M
Merk MRK:US $ 1497M 1517M
Minerva Neurosciences NERV:US $ -8.96M 1.46M
Moderna Inc MRNA:US 3.06B 1.8B
Novartis NVS:US $ 3479M 1064M
Novavax NVAX:US $ -345.83M 137.2M
Pain Therapeutics PTIE:US $ -5138000 1.6M
Peregrine Pharmaceuticals PPHM:US $ 6.93M 3.84M
Pfizer PFE:US $ 5914M 397M
Sarepta Therapeutics SRPT:US $ -167.57M 15.71M
Tg Therapeutics TGTX:US $ -77.49M 11.71M